New mechanism for regulating differentiation discovered in human embryonic stem cells

Researchers in the Center for Cancer Research have discovered a new mechanism involving a nuclease complex called the RNA exosome that represses differentiation of human embryonic stem cells. This represents the first time this mechanism has been studied in these cells. Read more...

Immunotherapy depicted with a cell

June is Cancer Immunotherapy Awareness Month

Jun 5, 2019

To celebrate Cancer Immunotherapy Month this June, we are highlighting our researchers who have helped pioneer this research and continue to make seminal advances in this growing field.  Read more...

June is Cancer Immunotherapy Awareness Month
Head and neck cancer regions

Investigators test combination therapy for head and neck squamous cell carcinoma in new trial

Jun 4, 2019

Patients with recurrent head and neck squamous cell carcinoma (HNSCC) may be eligible to participate in a new clinical trial at the NIH Clinical Center. This trial tests a therapy of a novel radiosensitizer, birinapant, in combination with radiotherapy for patients whose HNSCC has come back at or near the place of the original tumor. Read more...

Frontiers meeting info

Registration now open for Frontiers in Light Microscopy

Jun 3, 2019

The Frontiers in Light Microscopy conference is a platform to discuss the latest advances in microscopy and biological imaging.  The current state of the art in light microscopy will be presented by leading researchers in the field who will cover topics such as intravital imaging, super-resolution microscopy and light sheet microscopy. Sessions will include organelle dynamics and function, multicellular organisms and imaging the immune system. Read more...

Registration now open for Frontiers in Light Microscopy
Drawing of inside of brain

Clinical trial tests a new drug therapy for recurrent ependymomas of the brain and spinal cord

May 28, 2019

Ependymomas are rare tumors that arise in the ependyma, the thin membrane that lines fluid-filled cavities in the brain and spinal cord, and there are limited treatment options for those that have already been treated with standard therapies. A new clinical trial is testing a drug that targets ependymomas that have a specific genetic signature. Read more...

Nataliya Buxbaum

Nataliya Buxbaum wins Magnetic Moments video competition

May 22, 2019

Nataliya P. Buxbaum, M.D., Assistant Clinical Investigator in the Experimental Transplantation and Immunology Branch, was named the overall winner of the International Society for Magnetic Resonance in Medicine’s Magnetic Moments Competition. The competition is designed for investigators to use video to describe their MRI-related research for a general audience. Dr. Buxbaum’s video describes her research using tracers to better and more safely image tumors.  Read more...

Nataliya Buxbaum wins Magnetic Moments video competition
Doctor with patient

Clinical study follows men with specific genetic changes to determine their risk for developing prostate cancer

May 16, 2019

Prostate cancer (PC) is the most common malignancy in American men. There is increasing evidence that there may be a link between PC and men who have a family history of ovarian or breast cancer. As researchers have learned more about the role of genetics in PC, they have taken a new approach to screening for the disease—targeting men whose genetic profiles put them at risk for developing PC. Read more...

hepatocellular carcinoma

Clinical trial to determine whether antibiotics can boost immune response in treating liver cancer

May 14, 2019

A new clinical trial at the NCI’s Center for Cancer Research is set to explore if eliminating certain bacteria in the gut will boost the immune system response in patients who have hepatocellular carcinoma and liver metastases. 

  Read more...

Julius Strauss

Julius Strauss discusses promising immunotherapy drug for patients with HPV-related cancers

May 13, 2019

Julius Strauss, M.D., Assistant Research Physician in the Laboratory of Tumor Immunology and Biology, discussed a promising immunotherapy drug for patients with HPV-related cancers in a recent NCI Cancer Currents blog post. According to results from a phase 1 clinical trial, 33 percent of the 36 patients on the trial with HPV-positive tumors responded to the drug, and four of the responses lasted longer than 18 months. “This drug is a promising agent for patients with HPV-related cancers and may potentially benefit these patients more than traditional checkpoint therapies,” said Dr. Strauss. Read more...

Julius Strauss discusses promising immunotherapy drug for patients with HPV-related cancers
Screenshot of video on YouTube

Brid Ryan cohosts NCI Minority Health Month Facebook Live

May 13, 2019

The National Cancer Institute hosted a Facebook Live entitled, A Dialogue on Cancer Disparities, Prevention, and Research.”The event featured Brid M. Ryan, Ph.D., M.P.H., Investigator in the Laboratory of Human Carcinogenesis, as well as Worta McCaskill-Stevens, M.D., M.S., from the Division of Cancer Prevention, and Christina Dieli-Conwright, Ph.D., M.P.H., from the University of Southern California. They discussed cancer disparities and the work being done to help reduce them. Read more...

Brid Ryan cohosts NCI Minority Health Month Facebook Live
Randy pictured with Julie Feurtado, RN

A patient’s 10-year journey to moxetumomab for hairy cell leukemia

May 8, 2019

Randy, a father, husband, engineering quality consultant and lifelong “Motor City” resident, was diagnosed with hairy cell leukemia in 1998 at the age of 41. After participation in a clinical trial at the NIH Clinical Center, his body has shown a complete response to the drug moxetumomab pasudotox, which was developed at the National Cancer Institute’s Center for Cancer Research. Read more...

Pages